Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran (SKU B6848) is a selective agonist for human HM74A/GPR109A and GPR109B receptors, central to lipid metabolism regulation (Ye et al., 2025). Its defined structure, (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, enables precise receptor modulation (APExBIO). Cryo-EM studies confirm Acifran's direct binding to HCAR2 and HCAR3 orthosteric sites. The compound is validated for use in lipid signaling pathway assays and metabolic disorder models. Supplied by APExBIO at ≥98% purity, Acifran provides reproducible results under controlled storage and handling (APExBIO).

Biological Rationale

Hydroxycarboxylic acid receptors (HCARs), including HM74A/GPR109A (HCAR2) and GPR109B (HCAR3), regulate lipid metabolism and energy homeostasis in humans (Ye et al., 2025). These G-protein coupled receptors (GPCRs) are selectively activated by endogenous metabolites and synthetic agonists. HCAR2 activation is a clinically validated target for dyslipidemia therapy, while HCAR3 provides a distinct pharmacological profile with lower risk of cutaneous flushing (entinostat.net – this article extends the mechanistic detail with new structural data). Acifran’s selectivity for both receptors enables comparative studies of lipid signaling and metabolic disease models. Its defined activity allows for the dissection of receptor-mediated pathways in vitro and in vivo (n3-kethoxal.com; this article provides updated benchmarks and structure-function analysis).

Mechanism of Action of Acifran

Acifran binds the orthosteric site of HCAR2 and HCAR3 with high specificity, as demonstrated by cryo-EM structures at 2.72 Å and 3.18 Å, respectively, under buffered conditions at 4°C (Ye et al., 2025). Key residues involved in Acifran binding include F1073.32 and V/L832.60 (Ballesteros-Weinstein numbering), which influence ligand selectivity and affinity. The compound acts as a G-protein coupled receptor (GPCR) agonist, promoting Gi-protein activation and leading to decreased intracellular cAMP levels in HEK-293 cells. This cascade results in the suppression of lipolysis and modulation of lipid homeostasis. Acifran’s selectivity profile distinguishes it from HCAR2-selective agonists, providing a unique tool for dissecting receptor-specific signaling mechanisms (entinostat.net – this work adds structural context over previous protocol guides).

Evidence & Benchmarks

• Acifran directly occupies the orthosteric pockets of both HCAR2 and HCAR3, as resolved by cryo-EM (2.72–3.18 Å), confirming molecular interaction sites (Ye et al., 2025).
• In HEK-293 cell cAMP assays, Acifran exhibits concentration-dependent activation of HCAR2 and HCAR3 at EC50 values in the low micromolar range (Ye et al., 2025).
• Product purity is validated at 98.00% by HPLC, supporting reproducibility in cell-based and biochemical assays (APExBIO).
• Acifran’s solubility is below 21.82 mg/ml in ethanol and DMSO at room temperature, enabling preparation of high-concentration stocks (APExBIO).
• Storage at -20°C with blue ice preserves compound integrity for shipment and short-term use (APExBIO).
• Cryo-EM datasets and atomic models for Acifran–HCAR complexes are deposited under PDB codes 9JKY (HCAR2) and 9JKX (HCAR3) (Ye et al., 2025).

Applications, Limits & Misconceptions

Acifran is used as a reference agonist in studies of lipid signaling, hypolipidemic agent screening, and metabolic disorder modeling. Its selectivity for both HCAR2 and HCAR3 enables side-by-side comparison of receptor pharmacology. Key application areas include cell viability assays, cAMP signaling measurements, and lipid homeostasis studies (moleculeprobes.net; this article builds on practical assay troubleshooting with new structural evidence).

Common Pitfalls or Misconceptions

• Acifran is not suitable for long-term solution storage; activity degrades after 24 hours at room temperature or 4°C (APExBIO).
• It is not intended for diagnostic, therapeutic, or in vivo clinical use due to regulatory and safety boundaries (APExBIO).
• Acifran’s selectivity does not extend to all GPCRs; off-target effects in non-HCAR contexts are rare but possible at high concentrations.
• The compound’s solubility limit in aqueous buffer is low; precipitation can occur if not properly dissolved in DMSO or ethanol first.
• Interpretation of cAMP reduction must control for cell line background and endogenous GPCR expression (Ye et al., 2025).

Workflow Integration & Parameters

Acifran is supplied as an off-white solid, molecular weight 218.21 Da, C12H10O4 (APExBIO). To prepare working stocks, dissolve in DMSO or ethanol at concentrations up to 21.82 mg/ml. Store solid at -20°C; use solutions immediately for best activity. For cell-based assays, Acifran is typically added at 1–10 μM final concentration. Controls should include vehicle and known agonists for comparison. APExBIO ensures batch-to-batch consistency and provides purity documentation. For protocol troubleshooting, see scenario-driven guidance at moleculeprobes.com (this guide is extended here with new structural benchmarks and product handling parameters).

Conclusion & Outlook

Acifran is a validated, selective tool compound for dissecting HCAR2/HCAR3-mediated lipid signaling. Structural and functional data support its use in lipid metabolism and metabolic disorder research. The product’s stability, purity, and reproducibility make it a preferred reference agonist for mechanistic and translational studies. Ongoing advances in receptor structure-function analysis may further refine its applications and guide the design of next-generation, receptor-specific hypolipidemic agents.